Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Nutrition 21’s loss dwindles

This article was originally published in The Tan Sheet

Executive Summary

Consumer purchases of Iceland Health formulas at retail increased 29 percent in the firm's fiscal 2009 third quarter, more than triple the growth of the vitamin-mineral-supplement category. The Purchase, N.Y.-based company reports in an earnings release May 12 that net revenue fell 20.4 percent to $8.6 million from the year-ago quarter primarily due to "turbulent economic conditions." The company narrowed its losses during the January-March period, however, with a net loss of $400,000 compared to a loss of $8.2 million in third quarter fiscal 2008. Nutrition 21 says it expects an increase in revenues and is "building considerable leverage and sustainability into our operating model." The firm is "demonstrating that our combination of strong branding, safe and efficacious products, and effective marketing support are driving strong results," according to President and CEO Michael A. Zeher

You may also be interested in...

Did Sarepta Need To Tell Investors About Its Vyondys 53 Dispute Resolution Request?

Attorneys say Sarepta did not have an obligation to report its appeal, particularly since winning a formal dispute filing with the US FDA is a long shot.

Sarepta’s Vyondys: Renal Toxicity Concerns That Delayed Approval Get Enhanced Postmarketing Scrutiny, Label Warning

Sarepta must perform enhanced pharmacovigilance for serious renal toxicity events and rhabdomyolysis with the Duchenne muscular dystrophy drug, which carries a label warning for renal toxicity. Approval letter includes 2024 target completion date for ESSENCE confirmatory trial.

Horizon's Teprotumumab Breezes Through US FDA Adcom, But Safety Questions Remain

Efficacy data were striking to committee members, but they want to ensure postmarketing plans gather adequate data to address safety questions.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts